M&A Deal Summary

Aevi Genomic Medicine Acquires NeuroFix Therapeutics

On September 9, 2015, Aevi Genomic Medicine acquired life science company NeuroFix Therapeutics for 2M USD

Acquisition Highlights
  • This is Aevi Genomic Medicine’s 1st transaction in the Life Science sector.
  • This is Aevi Genomic Medicine’s largest (disclosed) transaction.
  • This is Aevi Genomic Medicine’s 1st transaction in the United States.

M&A Deal Summary
Date 2015-09-09
Target NeuroFix Therapeutics
Sector Life Science
Buyer(s) Aevi Genomic Medicine
Deal Type Add-on Acquisition
Deal Value 2M USD

Target

NeuroFix Therapeutics

United States
NeuroFix Therapeutics LLC is a developer of NFC-1, a non-stimulant metabotropic glutamate receptor (mGluR) neuromodulator entering Phase 2/3 for the treatment of mGluR network mutation positive Attention Deficit Hyperactivity Disorder (mGluR+ ADHD).

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Aevi Genomic Medicine

Wayne, Pennsylvania, United States
Category Company
Founded 2000
Sector Life Science
Employees14
DESCRIPTION

Aevi Genomic Medicine, Inc. is a biopharmaceutical company developing a technology platform for the purpose of treating patients with rare and orphan diseases. Driven by a commitment to patients with pediatric-onset life-altering diseases, Aevi’s research and development efforts include working with the Center for Applied Genomics (CAG) at Children’s Hospital of Philadelphia to leverage novel genetic discoveries to progress its genomic medicine strategy. Aevi Genomic Medicine was founded in 2000 and is based in Wayne, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
Country (United States) 1 of 1
Year (2015) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal